Controlling Pandora\u27s Box: The Need for Patent Protection in Transgenic Research by Quick, John J.
University of Miami Law School
Institutional Repository
University of Miami Business Law Review
7-1-2007
Controlling Pandora's Box: The Need for Patent
Protection in Transgenic Research
John J. Quick
Follow this and additional works at: http://repository.law.miami.edu/umblr
Part of the Law Commons
This Article is brought to you for free and open access by Institutional Repository. It has been accepted for inclusion in University of Miami Business
Law Review by an authorized administrator of Institutional Repository. For more information, please contact library@law.miami.edu.
Recommended Citation
John J. Quick, Controlling Pandora's Box: The Need for Patent Protection in Transgenic Research, 15 U. Miami Bus. L. Rev. 303 (2007)
Available at: http://repository.law.miami.edu/umblr/vol15/iss2/6
CONTROLLING PANDORA'S BOX: THE NEED FOR
PATENT PROTECTION IN TRANSGENIC RESEARCH
JOHNJ. QUICK
I. INTRODUCTION ..................................... 303
II. GENETIC RESEARCH ................................. 304
A. A Brief Overview ................................. 304
B. Transgenic Research ................................ 304
C. The Human Genome Project ......................... 306
III. THE FOUR CURRENT MEANS OF PROTECTING
GENETICALLY MODIFIED ORGANISMS ................... 307
A. The Plant Patent Act And The Plant Variety Protection Act... 307
B. Trade Secret Law ................................. 309
C . Utility Patents .................................... 310
IV. ACTION BYTHE PTO ................................. 312
V. ARGUMENTS AGAINST THE PATENTING OF TRANSGENIC
AN IM ALS ........................................... 313
VI. A PROPOSED SOLUTION FOR PROTECTING TRANSGENIC
RESEARCH .......................................... 314
VII. CONCLUSION ....................................... 315
I. INTRODUCTION
With the emergence of biotechnology and the ability to manipulate
genetic material, the patenting of living organisms is becoming an area of
increased interest.' The creation of the Human Genome Project has served
to further intensify the debate over the patenting of living organisms.
This paper will serve as a guided tour through the present status of
transgenic research, the laws, and proposed laws created to regulate it. Part
B will provide a brief overview ofbiotechnology, transgenic research and the
Human Genome Project. Part C of this paper will generally explore the
John J. Quick is an associate with the law firm ofWeiss, Serota, Helfman, Pastoriza, Cole &
Boniske, P.L. in Miami, Florida. J.D., Boston University School of Law; B.A., University of California,
Los Angeles. Some of his recent pertinent publications include: Genetic Discrimination and the Need for
Federal Legislation, J. BIoLAw & Bus., Vol. 8, No. 1, 2005; and Intellectual Property: Plants Patentable Under
the Utility Patent Statute, PVA, and PVPA, 30 J.L. MED. & ETHICS 317, 2002. Mr. Quick would like to
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I Rebecca Dresser, Ethical and Legal Issues in Patenting New Animal Life, 28JURIMETRICSJ. 399,
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four current legal means of protecting genetically modified organisms.
These means of protection include the Plant Patent Act, the Plant Variety
Protection Act, the Utility Patent Act and trade secret law. Part D of this
paper will provide a historical recounting of actions taken by the United
States Patent and Trademark Office. Part E will discuss and rebut various
arguments against transgenic research. Finally, Part F will propose an
amendment to provide for specific patent protection for transgenic research.
II. GENETIC RESEARCH
A. A Brief Overview
In 1953, the discovery of DNA by J. D. Watson and Francis Crick
created the fuel for the intellectual fire of transgenic research. Watson and
Crick's discovery of DNA's3 presence in all living organisms led to
numerous scientific advances.4 The discovery of the double-helix enabled
scientists to better understand individual gene characteristics and the results
attributed to the expression of each gene.' It has also permitted scientists to
genetically modify an organism through genetic engineering, which "allows
for the recombination of genetic material of more than one organism."
6
B. Transgenic Research
Transgenic research involves modification to plants, animals and
microorganisms. Commonly known as transgenic testing,' this process
2 EdmundJ. Sease, From Microbes, to Corn Seeds, to Oysters, to Mice: Patentability of New Life Forms,
38 DRAKE L. REV. 551, 552 (1988-1989).
3 For a more detailed discussion regarding DNA, see Andrew Chin, Research in the Shadow of
DNA Patents, 87 J. PAT. & TRADEMARK OFF. Soc'Y 846, 848-53 (2005).
4 Jerzy Koopman, The Patentability of Transgenic Animals in the United States of America and the
European Union:A Proposalfor Harmonization, 13FORDHAMINTELL. PROP. MEDIA &ENT. L.J. 103, 111-
12 (2002).
s Id. at 106.
6 Id. at 112.
See generally John M. Moye, Recent Development, The Court of Appeals of North Carolina's
Narrow Approach to Trade Secrets Protection in North Carolina Farm Partnership v. Pig Improvement Company,
83 N.C. L. REv. 1567,1586 (2005);James F. Ewing, Agricultural Biotechnology: Is the International Regulation
of Transgenic Agricultural Plants for the Birds (and the Bees)?, 25 SUFFOLK TRANSNAT'L L. REv. 617 (2002);
Jon Owens, The Future oftheAnimal Rights Movement: Environmental Conflict, Artificial Intelligence, andBeyond,
33 ENVTL. L. REV. 10265 (2003); Sease, supra note 2; D.L. Uchtmann, Starlinktm - A Case Study of
Agricultural Biotechnology Regulation, 7 DRAKEJ. AGRIC. L. 159 (2002).
8 Kevin W. O'Connor, Patenting Animals and Other Living Things, 65 S. CAL. L. REV. 597, 608
(1991).
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enables scientists to implant human genes into an organism allowing
scientists to test the reaction of that human gene without using human test
subjects.9
There are two forms of transgenic creation., ° The first, and at present,
most common is that of microinjection." The process of microinjection
involves the extraction of a gene "from one organism using special bacterial
enzymes capable of slicing a DNA molecule at the appropriate place."' 2
Purified gene copies are then injected "into a fertilized single-cell egg of
another species," which is then implanted into a female of the same species.'
3
Each developing cell of the newly born animal will then develop to contain
the implanted gene.14
The second form oftransgenic creation involves embryo fusion.'" This
method is completed by combining the cells of two organisms and then
implanting the newly fused cell into a surrogate mother, which is a species
of one of the two cell types.' 6 This method does not produce genetically
identical offspring, instead producing offspring that will resemble one of the
two combined organisms.' 7
There are three major areas in which transgenic research may exhibit
commercial value.' 8 First, transgenic research may help to further develop
the agriculture industry by expediting the benefits derived from classic
animal breeding.1 9 Additionally, transgenic animals may be used to increase
the productivity of common farm animals. 2 These improvements may
include heightened resistance to disease, alterations to muscle mass or size
and the creation of more protein-filled milk.2'
9 Dresser, supra note 1, at 405-06.
1o See Carolyn A. Schmotzer, Assessment of Murine Embryo Development Following
Electroporation and Microinjection of a Green Fluorescent Protein DNA Construct (July 31, 2001)
(unpublished M.S. thesis, Virginia Polytechnic Institute and State University), at
http //scholar.lib.vt.edti/theses/available/etd-08062001-122413/unrestricted/FinalThesisforETD.pdf
t Dresser, supra note 1, at 405.
12 Id.
13 Id.
14 Id.
15 Id. at 406.
16 Id.
17 Id. at 406-07.
is Id. at 407.
19 Id.
20 Koopman, supra note 4, at 115.
21 Thomas Traian Moga, Transgenic Animals as Intellectual Property (Or the Patented Mouse that
Roared), 76J. PAT. & TRADEMARK OFF. Soc'y511, 530-31 (1994).
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Second, transgenic organisms can assist the advancement of biomedical
research. 22 Most importantly, scientists may utilize transgenic animals as "a
fundamental tool for studying human disease and its treatment."'3 In fact,
scientists are already using transgenic research in an attempt to cure human
albinism by altering the embryos of albino mice to ensure that each altered
embryo grows into a regularly-pigmented mouse.24 Additionally, transgenic
research may allow scientists to further expand the Human Genome
database through studies of specific genes implanted in animals. 2 Such
research could enable scientists to further study gene expression when
attempting to treat hereditary diseases in humans.
26
Third, transgenic animal research may have a positive effect upon the
environment.7 Through genetic alteration, scientists may be able to modify
an organism's internal functions so as to lessen the organism's discharge28 or
enable it to break down potentially harmful material, thereby reducing the
overall impact upon the environment.29
C. The Human Genome Project
The constant desire of scientists to better understand the living world
led to the United States Department of Energy and the National Institute of
Health ("NIH") establishing the Human Genome Project in 1990.30 This
coordinated federally-funded project began to "enhance the ability to gather
and organize information that may predict a person's future potential and
disabilities."3' The key goal of the Human Genome Project is "to determine
the sequence of the three billion chemical base pairs that make up the
human DNA and to identify the approximately 35,000 genes in human
DNA."32 Completion of this goal was originally scheduled for 2005,33
22 Dresser, supra note 1, at 407.
23 Id.
24 Koopman, supra note 4, at 114.
25 Elizabeth Joy Hecht, Beyond Animal Legal Defense Fund v. Quigg: The Controversy Over
Transgenic Animal Patents Continues, 41 Am. U. L. REV. 1023, 1037 (1992).
26 Dresser, supra note 1, at 408.
27 Id. at 407.
2S Koopman, supra note 4, at 116.
29 Id. at 116-17.
30 Jeremy A. Colby, An Analysis of Genetic Discrimination Legislation Proposed by the 105th Congress,
24AM.J.L. &MED. 443,445 (1998).
31 Larry Gostin, Genetic Discrimination: The Use of Genetically Based Diagnostic and Prognostic Tests
by Employers and Insurers, 17AM.J.L. & MED. 109, 110 (1991).
32 Robert A. Curley, Jr. and Lisa M. Caperna, The Brave New World is Here: Privacy Issues and the
Human Genome Project, 70 DEF. COUNS.J. 22, 23 (2003).
33 Colby, supra note 30, at 445.
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however, "rapid technological advances accelerated the completion date to
2003. "3 4 These 35,000 genes comprise forty-six strands of DNA3" which
make up each human cell36 and are grouped into twenty-three pairs.37
The Human Genome Project was established to map each
chromosome31 in order to identify an area on the chromosome that indicates
which trait the gene will express. 39 This map will allow scientists to detect
altered genes that predispose4° an individual to certain genetic diseases.4 '
Once completed, this project will allow scientists from across the globe to
conduct transgenic research and compare and contrast the reactions of each
transgenically implanted human gene.42
HI. THE FOUR CURRENT MEANS OF PROTECTING GENETICALLY
MODIFIED ORGANISMS
There are four main legal methods to protect genetically modified
organisms.43 These methods are: (1) the Plant Patent Act of 1930 ("PPA");44
(2) the Plant Variety Protection Act of 1970 ("PVPA");45 (3) the use of trade
secret law;46 and (4) the Utility Patent Act ("UPA").47
A. The Plant Patent Act And The Plant Variety Protection Act
As its name insinuates, the PPA protects only genetically-modified plant
species. 48 Patent protection is extended only if the scientist can show that
34 About the Human Genome Project, at http://www.ornl.gov/sci/techresources/Human_
Genome/project/ about.shtml (last visited March 2, 2007).
35 Also known as chromosomes. See supra note 30, at 446.
36 Curley & Caperna, supra note 32, at 23.
37 Colby, supra note 30, at 446.
38 The process of mapping is the assignment of genes to specific chromosomes. Id. at 447.
39 Id.
40 It is important to note that a predisposition to certain genetic diseases does not indicate a
certainty ofcontracting that genetic disease. See Thomas F. Wieder, Privacy Protection is Neededfor DNA,
2002 L. REv. MICH. ST. U. DET. C.L. 927, 931 (2002).
41 Paul Steven Miller, Is There a Pink Slip in my Genes? Genetic Discrimination in the Workplace, 3
J. HEALTH CARE L. & POL'Y 225, 229 (2000).
42 See generally Gostin, supra note 31.
43 O'Connor, supra note 8, at 604-07.
44 Pub. L. No. 71-245, 46 Stat. 376 (codified as amended at 35 U.S.C. S 161-164 (1988)).
45 Pub. L. No. 91-577, 84 Stat. 1542 (codified as amended at 7 U.S.C. S 2321-2583 (1988)).
46 See generally Andrew Beckerman-Rodau, The Choice Between Patent Protection and Trade Secret
Protection: A Legal and Business Decision, 84J. PAT. & TRADEMARK OFF. Soc'Y 371, 379-380 (2002).
47 35 U.S.C. S 101 (2000), et seq.
48 SeeJohn M. Czarnetzky, Altering Nature's Blueprintsfor Profit: Patenting MulticellularAnimals, 74
VA. L. REV. 1327, 1341-42.
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the plant is a "new and distinct asexually propagated variet[y] other than
tuber propagated plants."49 The PPA explicitly states that it does not apply
to plants propagated through seed, as it was originally thought that seed was
incapable of producing a truly similar type.
50
Congress extended the protection of the PPA to include sexually-
reproduced plants through its enactment of the PVPA.5' Congress enacted
this statute to provide financial incentive as a means to stimulate new
development of sexually reproduced plants within the commercial sector.5 2
The protection afforded under the PVPA, however, is not officially a
patent.53 Instead, plant variety certificates are issued by the United States'
Department of Agriculture for any "novel variety of [a] sexually reproduced
plant. ... ",4
The PVPA, however, does exempt two categories of people for
certificate infringement.5 5 First, the PVPA provides an exemption for
farmers, whose primary occupation is the sale of homegrown crops.5 6 This
exemption allows a farmer to maintain a stockpile of seed for the use of
growing crops on the farm. 7 Second, the PVPA also provides an exemption
for researchers, allowing for the use of the certificated seed for the sole
purpose of developing a new seed variety."
The PPA and the PVPA provide much needed protection for both
inventors and investors of genetic research, but this protection remains too
limited in scope. PPA and PVPA protection affords only limited safeguards
to a narrow group of living organisms. Moreover, the protection provided
by each extends only to plants and does not protect genetic research
involving other forms of living material. As a result, specific statutory
protection of transgenic animals does not exist.
49 O'Connor, supra note 8, at 604 (stating that since the enactment of the PPA, the United States'
Patent and Trademark Office has issued over six thousand plant patents).
so Id.
51 Id. at 605.
52 Id.
53 Id.
54 Id. (Plant variety protection does not extend to a limited number of novel plant varieties,
including fungi, bacteria or first generation hybrid).
55 Pub. L. No. 91-577, 84 Stat. 1542 (codified, as amended, at 7 U.S.C. S 2544 (1988)).
56 O'Connor, supra note 8, at 605.
57 Id.
58 Id. (stating since the enactment of the PVPA, the United States' Department of Agriculture
has issued 1,850 protection certificates while 260 applications remain pending).
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B. Trade Secret Law
The use of trade secret law provides a broader means of protection. 9
Trade secret law6° is an attractive mode of protection since no eligibility
requirements for protection exist. 61 Moreover, with a potentially limitless
timeline, it offers permanent protection to the inventory Trade secret law
views protectable subject matter through a functional definition. 63 A trade
secret can include almost anything so long as the company maintains the
subject matter as a secret, it is not commonly known by competitors, and it
would provide the company with a competitive advantage.'
The creation of a trade secret rather than a patent may be desirable to a
company because unlike patents, a trade secret does not require the
publication of the subject matter within eighteen months of the application
for patent protection.65 Furthermore, the extent of patent protection appears
to be under attack in at least one jurisdiction. The First Circuit Court of
Appeals limited the Doctrine of Equivalence,' holding that by narrowing a
claim to obtain a patent, prosecution estoppel serves as a bar to suit against
every equivalent claim of that nature.67
The United States Supreme Court, however, has quashed this
movement for the moment.' In so doing, the Court announced that while
prosecution estoppel requires that claims be interpreted in light of
underlying proceedings in the patent office during the application process,
s9 Mark W. Lauroesch, Genetic Engineering: Innovation and Risk Minimization, 57 GEo. WASH. L.
REV. 100, 107-09 (1988).
60 It is important to note that trade secret law does not necessarily provide limitless protection.
Courts in at least one state have held that under certain circumstances "trade secrets" may be subject to
discovery under public records laws. See Cubic Transp. Systems, Inc. v. Miami-Dade County, 899 So. 2d 453
(Fla. 3d DCA 2005); Sepro Corp. v. Fla. Dept. of Environ. Protection, 839 So. 2d 781, 784 (Fla. 1st DCA
2003).
61 Beckerman-Rodau, supra note 46, at 379-80.
62 Lauroesch, supra note 59, at 107.
63 Beckerman-Rodau, supra note 46, at 379.
6 Id.
65 Id. at 381.
66 The Doctrine of Equivalence "prohibits a would-be infringer from making an 'insubstantial'
modification to a product, method, etc., to avoid infringement of a patent claim." Scott M. Alter, Festo
and the Future of the Doctrine of Equivalence, 735 PLIPAT 45, 48 (2003).
67 See Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 234 F.3d 558 (1st Cir. 2000), vacated,
Festo Corp. v. Shoketsu Kinzo Kogyo Kabushiki Co., 535 U.S. 722 (2002)).
68 See generally Festo Corp., 535 U.S. 722 (2002).
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a narrowing amendment made during patent prosecution does not bar all
equivalents from suit.69
The use of trade secret protection would have far reaching consequences
on the scientific community, as well as the population at large. If trade
secret protection becomes the preferred means of transgenic research
protection, there would be a strong incentive for scientists not to disclose
their breakthroughs. 0 Moreover, a company would have to shift money that
could be used for innovation and discovery to the protection of the trade
secret.7 '
While this means of protection will maximize the profit potential of a
researcher or company, it will consequently slow the exchange of
information within the scientific community.72 Furthermore, the use of
trade secrets will create unnecessary waste within the scientific community
by requiring that separate researchers expend otherwise unnecessary time
and money in duplicating a particular trade secret.73 Similarly, the existence
of trade secrets will harm the public as a whole. Allowing one company to
establish an indefinite monopoly on a scientific discovery effectively bars the
vast majority of the population from access to the discovery.
C. Utility Patents
The UPA provides that the United States Patent and Trademark Office
("PTO") is to be the entity to oversee all patent applications.74 Section 101
of the UPA provides a broad definition of patentable matter by explaining
that "whoever invents or discovers any useful process, machine,
manufacture, or composition of matter or any new and useful improvement
thereof, may obtain a patent therefore ... ."75 The UPA, then, specifies
three additional requirements before the PTO may issue a patent.76
69 Id. at 740-41.
70 Lauroesch, supra note 59, at 108.
71 Id.
72 Id.
73 Id.
74 35 U.S.C. S S 1-376 (2000).
75 35 U.S.C. S 101 (2000).
76 Seegenerally Czarnetzky, supra note 48, at 1334-35; Koopman, supra note 4, at 119-21. For an
example of a living organism which meets these three requirements, see Mikyung Kim, An Overview of
the Regulation and Patentability of Human Cloning and Embryonic Stem Cell Research in the United States and
Anti-Cloning Legislation in South Korea, 21 SANTA CLARA COMPUTER & HIGH TECH. L.J. 645, 697-98
(2005).
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First, the prospective patentable organism must "have some utility apart
from research."77 This prerequisite requires that the organism be a "new and
useful.., composition of matter .. ,,." This portion of the statute was
established to provide some minimal requirement for patent application.
The second prerequisite requires that the organism fulfill the novelty
requirement as established under Section 102 of the UPA.79 The UPA
defines novel as something that does not already exist.80 This requirement
will not be met if the organism is both naturally occurring and considerably
unaltered.8 1 This prerequisite further requires that the organism meet three
separate conditions: general utility, specific utility and beneficial utility.
8 2
General utility requires that the organism/invention be operable and capable
of general use.83 Specific utility mandates that the organism/invention be
able to solve the problem it is designed to correct.' Lastly, the beneficial
utility requires that the organism/invention, at a minimum, provide some
overall societal benefit.'5
The third UPA prerequisite requires that the organism fulfill a non-
obvious requirement.8 6 In order to successfully satisfy this requirement, the
newly created organism must not have been open and obvious to anyone
other than the inventor.' In establishing non-obviousness, courts take into
account three factors. 8 Courts first consider the content and scope of any
prior similar inventions.8 9 Second, courts consider what differences exist,
if any, between the organism/invention at issue and prior inventions.90 Last,
courts look to ensure that the inventor surpassed the level of ordinary skill
existing in the area of invention.91
7 Czarnetzky, supra note 48, at 1335.
78 35 U.S.C. § 101 (2000); See Brenner v. Manson, 383 U.S. 519, 528-31 (1966).
79 35 U.S.C. 5102 (2000).
so Id.
81 PATENT AND TRADEMARK OFFICE, U.S. DEP'T OF COMMERCE, MANUAL OF PATENT
EXAMINING PROCEDURE § 706.03(a) (2006).
82 ROBERT PATRICK MERGES, PATENT LAWAND POLICY 189 (1982).
83 Id.
8 Id.
85 Id.
86 35 U.S.C. § 103 (2000).
7 Id.
a0 See generally Graham v.John Deere Co., 383 U.S. 1, 17-18 (1966); Custom Accessories Inc. v.Jeffrey-
Allan Indus. Inc., 807 F.2d 955, 958 (Fed. Cir. 1986).
89 Graham, 383 U.S. at 17; Custom Accessories, 807 F.2d at 958.
90 Graham, 383 U.S. at 17; Custom Accessories, 807 F.2d at 958.
91 Graham, 383 U.S. at 17; Custom Accessories, 807 F.2d at 958.
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Patent protection's biggest drawback to investors is the twenty-year
statutory length of the patent.' However, during the twenty-year period the
researcher is granted an exclusive right to produce the patented organism.93
While an investor may be scared off by the possibility of a return-on-
investment limited to twenty years after the time application is filed, this
period still allows a researcher to sell the use rights of the patent to any
number of other researchers. Furthermore, this requirement allows for the
full disclosure of the processes of creation. The exclusive ownership period
benefits both the research community and public as a whole by enabling
researchers to bypass the mistakes made in prior research and build upon
what has already been established.
IV. ACTION BY THE PTO
In the past, the PTO rejected attempts to patent such innovations as
headless shrimp on the grounds that the alterations were not sufficiently
permanent.94 Moreover, the PTO has previously stated that no living
organism is eligible for patenting because the Product of Nature Doctrine
preempts patentability.9"
The first major case involving the granting of utility patents for living
organisms occurred in Diamond v. Chakrabarty.96 The Supreme Court in
Chakrabarty found that since Congress enacted the UPA in such broad
terms, § 101 must be read so as to extend patent protection to living
organisms.97 The Court further stated that until Congress specifically speaks
to the subject, the Court will view the UPA as extending patent protection
to living organisms.
98
Another court held that the PTO further expanded the category of
patentable matter when, in approving an application, it overrode an
examiner's rejection of larger-than-normal oysters.' Relying on
Chakrabarty, the PTO reasoned that since the PPA includes man-made
organisms, the oysters at issue were non-naturally occurring.1°° In a
statement, the PTO announced that all non-naturally occurring multi-
92 Beckerman-Rodau, supra note 46, at 383.
93 Id. at 387.
94 Koopman, supra note 4, at 124.
95 Id. at 123.
% Diamond v. Chakrabarty, 447 U.S. 303 (1980).
97 Id. at 309-10.
98 Id. at 317-18.
99 See In reAllen, 846 F.2d 77 (Fed. Cir. 1988).
100 Id.
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cellular, non-human organisms would be considered patentable under the
UPA.'0 ' Since that statement, the PTO has issued only a handful of patents,
covering specific animals, rather than classes or orders of animals.'
02
Most recently, inJ.E.M. AG Supply, Inc. v. Pioneer Hi-Bred International,
Inc.,' 03 the United States Supreme Court stated that utility patents are a
permissible means of protecting newly developed sexually-reproduced plants
and plant seeds."'O The Court found that in enacting both the PPA and the
PVPA, Congress did not limit the UPA's broad scope.' °5 The Court upheld
its previous holding in Chakrabarty in finding that since the UPA was written
in such broad terms, it was clearly Congress' intent to give the UPA a broad
scope.' °6 In so holding, the Court upheld the Appellate Court's ruling that
the UPA permits the patenting of living organisms.107 If this holding does
not already explicitly allow for the granting of utility patents for transgenic
animal research, it certainly opens the door for such a holding.0 8 Taken in
connection with the prior holdingsJ.E.MAG Supply appears to advance the
new trend of the patenting of transgenic animals.'
9
V. ARGUMENTS AGAINST THE PATENTING OF
TRANSGENIC ANIMALS
Most of the arguments against the patenting of living organisms tend to
focus on the moral and ethical issues involved. Viewing living organisms as
products is the most difficult concept with which many people grapple." 0
Critics of the inclusion of living organisms as patentable matter argue that
such inclusion degrades the value of life."' Critics further contend that
101 SeeJames P. Daniel, Of Mice and 'Manimal': The Patent & Trademark Office's Latest StanceAgainst
Patent Protection for Human-Based Inventions, 7 J. INTELL. PROP. L. 99, 116-18 (1999).
102 See Koopman, supra note 4, at 131-32.
103 534 U.S. 124 (2001).
104 Id. at 127.
105 Id. at 145.
106 Id.
107 Id. at 145-46.
100 See generally Velander v. Garner, 348 F.3d 1359 (Fed. Cir. 2003) (citing U.S. Patent No.
5,304,489 (filed Oct. 24 1990) and U.S. Patent No. 4,873,316 (filedJun. 23,1987) (denying patentability
of a transgenic animal, but doing so pursuant to UPA analysis); see also U.S. Patent No. 6,987,211 (filed
May 12,1999) (granting patent for"Transgenic non-human mammals producing a cholinesterase in their
milk"); see also U.S. Patent No. 6,953,874 (filed Feb. 5,2001) (granting patent for "Transgenic animals
having a modified glycoprotein V gene").
109 See Bratislav Stankovic, Patenting the Minotaur, 12 RICH. J.L. & TECH. 5, at *5 (2005)
(explaining that the PTO will not grant patents for human-animal chimera creations).
11o See Lauroesch, supra note 59, at 114-16.
III Id. at 114.
2007]
314 UNIVERSITY OF MIAMI BUSINESS LAW REVIEW [Vol. 15:303
viewing life as a commodity can be seen as continuing the systematic
submission of less powerful animals. This argument finds its support
primarily in the antiquated "morality doctrine" which prevents the patenting
of an invention "designed for an immoral use." 112 However, this morality
argument fails to acknowledge the history of man's ownership of animals
such as dogs, cows and sheep, and it necessarily fails.113
The second major criticism of patenting living organisms revolves
around the treatment of the patented material during testing. 114 However,
both federal and state laws prohibit the inhumane treatment of lab
animals."' Furthermore, if the PTO were to eliminate patents for living
organisms, the fear of inhumane lab treatment would not be cured."6
However, should the PTO eradicate such patents, it would severely impair
the societal benefits associated with laboratory research." 7
Thirdly, critics project negative future effects for allowing for the
patenting of living organisms. Many critics feel that by allowing the
patenting of non-human animals, the next logical step will be to include
genetically manufactured humans as patentable subject matter.118 This fear,
however, should remain unfounded, as it is unlikely that a court would
refuse to extend the Thirteenth Amendment" 9 to non-natural humans. 2°
VI. A PROPOSED SOLUTION FOR PROTECTING
TRANSGENIC RESEARCH
Transgenic research can allow scientists to better understand the
workings of the human body and specific genes. As a result, Congress must
enact a statute specifically protecting transgenic research. While trade secret
protection may provide sufficient security to a corporate researcher, it does
not advance the societal benefits associated with transgenic research.
Congress should instead either enact a new statute protecting transgenic
112 See Kim, supra note 76; see also Lowell v. Lewis, 15 F. Cas. 1018, 1019 (D. Mass. 1817);
Stankovic, supra note 109, at *36-44.
113 See Kim, supra note 76; see also Lowell, 15 F. Cas. at 1019; Stankovic, supra note 109, at *3&44.
114 Hecht, supra note 25, at 1041.
115 Lauroesch, supra note 59, at 117 (discussingthe Animal Welfare Act and guidelines established
by both the National Institute of Health and the American Association for Accreditation of Laboratory
Animal Care).
116 Id. at 118.
117 See Moye, supra note 7, at 1587-88.
118 Lauroesch, supra note 59, at 115.
119 U.S. Const. amend. XIII (protecting human beings from being subject to exclusive property
rights of another).
120 Lauroesch, supra note 59, at 115.
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research or amend the UPA so as to include transgenically produced animals
within the class of patentable subject matter.
Congress proposed legislation similar to the PVPA, in attempting to
create a farmers' exemption from protection.' 21 This exemption would
allow family farmers to reproduce the transgenic animals for the sole
purpose of breeding within their own farm. The exemption, however,
would not extend to reproduction with animals not presently owned by the
farmer. "
This exemption unfortunately may be an invitation to misuse. To
protect against such an outcome, this exemption needs to include a
moratorium on the sales of all reproduced transgenic animals by farmers.
Further, to ensure that the moratorium does not significantly harm the
farmer, its effectiveness would need to be for only a limited period after
birth. Otherwise, a farmer would be financially tied to the newborn animal.
This moratorium would be enacted in an attempt to close the loophole
created by the exemption. However, this loophole would not be closed
unless a moratorium on all sales is also enacted. Moreover, this moratorium
is not possible since it would severely damage most farmers. Since no clear
exemption is possible, Congress should not enact one.
Explicit patent protection for transgenic research is required so as to
keep the United States among the top countries in cutting edge research.
Such protection will promote the flow of information between researchers
and the publication of results. This will allow other researchers to duplicate
the tests previously conducted and improve upon those tests. Furthermore,
patent protection will provide researchers with adequate security and
encourage investor contribution. While some critics complain that patent
protection does not extend far enough, the alternatives would stifle research
everywhere. The most obvious and effective solution to this dilemma is a
Congressional amendment to the UPA which would include transgenically
produced and/or modified animals.
VII. CONCLUSION
Transgenic research, while in its infancy, promises to play an important
role in the future. The United States, as a scientifically-advanced nation,
must provide some protection to promote scientific innovation and
121 For a discussion of the proposed legislation, see Hecht, supra note 25, at 1066-68.
122 Regardless, Congress has been slow to act on any of these proposed bills. See, e.g., Brief for
the United States as Amicus Curiae Supporting the Respondents, at 17, Duke Univ. v. Madey, United
States Supreme Court (No. 02-1007), available at http;//www.uspto.gov/web/offices/com/soVambriefs/
Duke.pdf (last visited March 2, 2007).
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development in the area of transgenic research. Our current means of
protection do not provide sufficient guidance for the future, and Congress'
continued silence on the issue of patent protection for transgenic research
forces the PTO and the courts to speak on its behalf This should not be the
accepted means of deciding what can and should fall within the definition
of protected subject matter. Congress must speak so as to establish
guidelines for protection in order to quell potential fears of researchers,
investors and the public at large. Should Congress choose to remain silent,
a flood of research and investment potential could shift from the United
States to other parts of the world such as the European Union. In order to
protect against this, Congress should amend the UPA to include transgenic
research within the definition of patentable subject matter.
